Axon's 23% Rally Masks Persistent Margin and Valuation Risks

What happened

Axon shares surged 23.3% in the past month, fueled by strong Connected Devices and Software & Services growth, acquisitions, and an upwardly revised revenue outlook. However, the DeepValue report cautions that the stock at ~$496 prices in sustained high growth and margin delivery, while FY2025 showed GAAP operating deleverage and tariff-driven gross margin compression. The company’s long-term contracted backlog of $14.4B and 125% net revenue retention provide rare demand visibility, but deployment delays and cancellation clauses temper the certainty of conversion. Key risks include margin pressure from global tariffs, elevated stock-based compensation ($590M-$620M guided for FY2026), and the need for NRR to remain above 120% to support the growth algorithm. The surge narrows the margin of safety, reinforcing the WAIT rating with an attractive entry near $440 and a trim level above $620.

Implication

Investors should recognize that the 23% rally has pushed the stock further above our attractive entry zone of $440, reducing the margin of safety. The core bull case rests on sustained NRR ≥120% and successful conversion of the $14.4B backlog, but FY2026 guidance already embeds tariff headwinds and high SBC dilution. Near-term catalysts like Axon Week in April and the Axon Body Mini launch could sustain momentum, but any miss on NRR or margin guidance would invite multiple compression given the elevated P/E of 319x. The bear scenario of NRR falling below 115% and growth slowing to ~20% would imply a value of $380, a 23% downside from current levels. Until we see evidence that tariffs are contained and operating leverage materializes, the prudent stance is to wait for a better entry or confirmation of the bull case.

Thesis delta

The thesis remains WAIT; the recent price surge does not alter the fundamental risk-reward calculus. The stock is now closer to our trim zone ($620) than our attractive entry ($440), increasing the asymmetry to the downside. A shift to BUY would require NRR ≥120% and confirmation that FY2026 margin guidance is achievable.